Stock ARGX ARGENX SE
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases argenx SE

Equities

ARGX

NL0010832176

Real-time Euronext Bruxelles
Other stock markets
 05:41:33 2024-06-10 am EDT 		5-day change 1st Jan Change
348.2 EUR -1.80% Intraday chart for argenx SE +0.23% +1.37%
May. 30 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
May. 29 European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
GL
Argenx : argenx Reports First Quarter 2024 Financial Results and Provides Business Update
PU
Argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Argenx : argenx announces results of Annual General Meeting of Shareholders
PU
Argenx announces results of Annual General Meeting of Shareholders
GL
Argenx : argenx to Present at BofA Securities 2024 Health Care Conference
PU
Argenx to Present at BofA Securities 2024 Health Care Conference
GL
Argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GL
Argenx : argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
PU
Argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
GL
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
AQ
Argenx : argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
PU
Argenx : argenx Announces Annual General Meeting of Shareholders on May 7, 2024
PU
Argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GL
Argenx Announces Annual General Meeting of Shareholders on May 7, 2024
GL
Argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
GL
Argenx : argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
PU
Argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
GL
Argenx : argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
PU
Argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARGX Stock
  4. News argenx SE
  5. Press Releases